Loading
A phase 1/2 trial of Durvalumab, Carboplatin in small-cell lung cancer, run by IDEAYA Biosciences, now recruiting.
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07174583 by IDEAYA Biosciences, with 262 participants planned, started 2025-10-14 and due to reach its primary completion in 2029-07. Interventions recorded: IDE849, durvalumab, IDE161, Carboplatin. Conditions listed: Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Durvalumab, Carboplatin, Small-cell lung cancer.
Shares Durvalumab, Carboplatin, Small-cell lung cancer.
Shares Durvalumab, Small-cell lung cancer.
Shares Durvalumab, Small-cell lung cancer.
Shares Durvalumab, Small-cell lung cancer.
Shares Durvalumab, Carboplatin, Small-cell lung cancer.
Shares Durvalumab, Small-cell lung cancer.
Shares Durvalumab, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/